RespireRx Pharmaceuticals Inc (fka RSPI)

[jerrydylan]

it'll be higher, how much is anyone's guess. I believe closer to $15-20 million and some annual funding for the rights to low impacts in a laundry list of indications. Some nice back end deals and we can get going ADHD trials as well, that was clearly highlighted _"upon receipt of funding" thursday. Maybe they'll be able to hold on to High Impacts. I believe the stock price will react to the cache of the partner as well, which I am unable to predict-easier to say who it won't be.